Kralemont-LC Syrup Orange is a combination pharmaceutical formulation containing Levocetirizine dihydrochloride (2.5 mg per 5 ml) and Montelukast sodium (4 mg per 5 ml), indicated for the management of allergic conditions such as allergic rhinitis and asthma. Levocetirizine, a third-generation non-sedating antihistamine, selectively antagonizes peripheral H1 histamine receptors, thereby alleviating symptoms like sneezing, nasal congestion, rhinorrhea, and pruritus. Montelukast, a leukotriene receptor antagonist, inhibits the cysteinyl leukotriene receptor CysLT1, reducing bronchoconstriction, inflammation, and mucus production associated with asthma and allergic rhinitis. This synergistic combination provides comprehensive relief by targeting multiple inflammatory pathways involved in allergic responses. Kralemont-LC Syrup is particularly useful in pediatric patients requiring an effective, well-tolerated oral therapy for persistent allergic symptoms and asthma prophylaxis. The orange-flavored syrup formulation enhances palatability and compliance in children. Dosage should be individualized based on age and clinical response, and it is essential to adhere to prescribed regimens to achieve optimal therapeutic outcomes. Common adverse effects may include headache, somnolence, and gastrointestinal disturbances, though the combination is generally well tolerated. Patients with hepatic or renal impairment should use this medication cautiously under medical supervision.